Pharmaceutical care for a case of severe dermal toxicity induced by durvalumab

JI Liulian; QIN Zhengbi; LIU Pengcheng; DENG Xiaowen; LIU Lili; YAO Lijuan; LIU Tingting; GU Pingchen

doi:10.6039/j.issn.1001-0408.2026.01.16

您当前的位置：

首页 >

文章列表页 >

Pharmaceutical care for a case of severe dermal toxicity induced by durvalumab

更新时间：2026-02-10

- Pharmaceutical care for a case of severe dermal toxicity induced by durvalumab
- ZHONGGUO YAOFANG Vol. 37, Issue 1, Pages: 88-91(2026)
- 作者机构：
  
  1.盐城市第二人民医院肿瘤内科，江苏盐城;224000
  2.湖北民族大学医学部人文医学教研室，湖北恩施　445000
  3.中国药科大学国际医药商学院，南京　211198
  4.盐城市食品药品监督检验中心（药品不良反应监测中心），江苏盐城　224000
  5.盐城市第二人民医院药学科，江苏盐城　224000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.01.16
  CLC： R979.1;R969.3
- Received：10 September 2025，
  
  Revised：2025-12-16，
  
  Accepted：18 December 2025，
  
  Published：15 January 2026
- 稿件说明：
移动端阅览
季留连,覃正碧,柳鹏程,等.度伐利尤单抗致重度皮肤毒性反应1例的药学监护 [J].中国药房,2026,37(01):88-91.

JI Liulian,QIN Zhengbi,LIU Pengcheng,et al.Pharmaceutical care for a case of severe dermal toxicity induced by durvalumab[J].ZHONGGUO YAOFANG,2026,37(01):88-91.
季留连,覃正碧,柳鹏程,等.度伐利尤单抗致重度皮肤毒性反应1例的药学监护 [J].中国药房,2026,37(01):88-91. DOI： 10.6039/j.issn.1001-0408.2026.01.16.

JI Liulian,QIN Zhengbi,LIU Pengcheng,et al.Pharmaceutical care for a case of severe dermal toxicity induced by durvalumab[J].ZHONGGUO YAOFANG,2026,37(01):88-91. DOI： 10.6039/j.issn.1001-0408.2026.01.16.

摘要

目的

为正确识别、应对度伐利尤单抗致免疫相关皮肤毒性反应（irCAEs）及保障临床用药安全提供参考。

方法

临床药师参与度伐利尤单抗致1例胆囊癌患者发生irCAEs的诊治过程，通过系统查阅患者既往史、用药史，协助医生判断该不良反应与所用药物的关联性；同时，临床药师对该不良反应进行分级评估，提出停用度伐利尤单抗、调整糖皮质激素用法等建议，协助医生重启免疫治疗，并开展用药宣教等药学监护。

结果

该患者irCAEs的发生“很可能”与度伐利尤单抗相关，且为重度。医生采纳临床药师意见，患者经对症治疗后皮肤症状好转，带药出院。待患者糖皮质激素治疗结束后，医生以替雷利珠单抗重启免疫治疗，患者未再发生相关不良反应。

结论

度伐利尤单抗可导致重度皮肤斑丘疹等irCAEs。临床应及时寻找并停用可疑药物，立即采取有效的对症治疗措施并积极重启免疫治疗，以保证患者治疗的延续性和安全性。

Abstract

OBJECTIVE

To provide references for the accurate identification and management of immune-related cutaneous adverse events （irCAEs） caused by durvalumab， and ensuring safe clinical drug use.

METHODS

Clinical pharmacists participated in the diagnosis and treatment process of a patient with gallbladder cancer who developed irCAEs caused by durvalumab. The clinical pharmacists systematically reviewed the patient’s past medical history and medication history， and assisted physicians in assessing the association between adverse drug reactions and administered drugs. Meanwhile， the clinical pharmacists conducted a graded assessment of the adverse reaction， proposed recommendations such as discontinuing durvalumab and adjusting the administration regimen of glucocorticoids， assisted physicians in restarting immunotherapy， and carried out medication education and other pharmaceutical care.

RESULTS

The occurrence of irCAEs in this patient was “highly likely” related to durvalumab and was classified as severe. The physicians adopted the clinical pharmacist’s opinion， and after symptomatic treatment， the patient’s skin symptoms improved， and discharged with medication. After the completion of glucocorticoid therapy for the patient， the physician restarted immunotherapy with tislelizumab， and no related adverse reactions occurred again in the patient.

CONCLUSIONS

Durvalumab can cause irCAEs such as severe skin maculopapular rash. In clinical practice， it is crucial to promptly identify and discontinue suspicious drugs， immediately implement effective symptomatic treatment measures， and actively resume immunotherapy to ensure the continuity and safety of the patient’s treatment.

关键词

Keywords

references

霍丽曼，段杨洋，梁平，等 . 度伐利尤单抗联合化疗方案一线治疗晚期胆道癌的药物经济学评价 [J ] . 中国药房， 2025 ， 36 （ 17 ）： 2141 - 2147 .

CHENG Y ， SPIGEL D R ， CHO B C ， et al . Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer [J ] . N Engl J Med ， 2024 ， 391 （ 14 ）： 1313 - 1327 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）恶性血液病诊疗指南：2024 [M ] . 北京：人民卫生出版社， 2024 ： 512 .

JOHNSON D B ， NEBHAN C A ， MOSLEHI J J ， et al . Immune-checkpoint inhibitors：long-term implications of toxicity [J ] . Nat Rev Clin Oncol ， 2022 ， 19 （ 4 ）： 254 - 267 .

SEGER D ， BARKER K ， MCNAUGHTON C . Misuse of the Naranjo adverse drug reaction probability scale in toxicology [J ] . Clin Toxicol（Phila）， 2013 ， 51 （ 6 ）： 461 - 466 .

NCCN . Management of immune checkpoint inhibitor-related toxicities：version 2， 2024 [EB/OL ] . [ 2025-07-30 ] . https：//storage.yuntsg.com/pdf/guide_pdf/2024-11-12/1731399389835.pdf https://storage.yuntsg.com/pdf/guide_pdf/2024-11-12/1731399389835.pdf .

ESFAHANI K ， ELKRIEF A ， CALABRESE C ， et al . Mo- ving towards personalized treatments of immune-related adverse events [J ] . Nat Rev Clin Oncol ， 2020 ， 17 （ 8 ）： 504 - 515 .

吴滔，戴冽 . 靶向IL-6通路治疗免疫介导的炎症性疾病：从机制到临床 [J ] . 中山大学学报（医学科学版）， 2025 ， 46 （ 5 ）： 721 - 729 .

魏盈，李文凤，张宇飞，等 . 度伐利尤单抗注射液致脓疱型银屑病1例分析 [J ] . 中国药物警戒， 2025 ， 22 （ 9 ）： 1057 - 1060 .

施国明，黄晓勇，任正刚，等 . 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识： 2021版 [J ] . 中华消化外科杂志， 2021 ， 20 （ 12 ）： 1241 - 1258 .

KONG X Y ， CHEN L ， SU Z H ， et al . Toxicities associated with immune checkpoint inhibitors：a systematic study [J ] . Int J Surg ， 2023 ， 109 （ 6 ）： 1753 - 1768 .

孙毅，杨骥 . 肿瘤免疫检查点抑制剂引起皮肤不良反应多学科专家共识： 2025版 [J ] . 中国临床医学， 2025 ， 32 （ 2 ）： 306 - 321 .

中华医学会皮肤性病学分会，中国医师协会皮肤科医师分会，中国老年医学学会皮肤医学分会，等 . 免疫检查点抑制剂相关皮肤不良反应诊治中国专家共识： 2024版 [J ] . 中华医学杂志， 2024 ， 104 （ 20 ）： 1790 - 1803 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）免疫检查点抑制剂相关的毒性管理指南：2019 [M ] . 北京：人民卫生出版社： 2019 ： 28 - 31 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of immune checkpoint inhibitors versus routine second-line chemotherapy for advanced esophageal cancer ：a meta-analysis

Meta-analysis of the correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer

Meta-analysis of Non-immune Related Adverse Event s Caused by ICIs Alone or Combined with Routine Che- motherapy in the Treatment of Non-small Cell Lung Cancer

Case Analysis of 15 Cases of Immune-related Myocarditis Induced by Pembrolizumab

肿瘤免疫检查点抑制剂及其联合疗法的研究进展

Related Author

CAI Hongfu

LYU Peiyu

OUYANG Hua

GAN Shuirong

ZHANG Qingshu

HE Jiao

LIU Xiaobo

DAI Wei

Related Institution

No data

⁰